Advertisement


Jorge E. Cortes, MD, on Chronic Phase CML: Comparing Three Starting Doses of Ponatinib

EHA25 Virtual

Advertisement

Jorge E. Cortes, MD, of Georgia Cancer Center, discusses interim results from the OPTIC study, which showed a trend toward dose-dependent efficacy and safety, and may provide a refined understanding of the ponatinib benefit/risk profile and its relation to dose. Mature data from continued follow-up may support an alternate dosing regimen for patients with chronic phase chronic myeloid leukemia (Abstract S172).



Related Videos

Leukemia

Abhishek Maiti, MBBS, on AML: Decitabine and Venetoclax vs Intensive Chemotherapy

Abhishek Maiti, MBBS, of The University of Texas MD Anderson Cancer Center, discusses his analysis showing that 10-day decitabine and venetoclax led to superior outcomes comp...

Immunotherapy

Efstathios Kastritis, MD, on Amyloidosis: Daratumumab Plus Cyclophosphamide, Bortezomib, and Dexamethasone

Efstathios Kastritis, MD, of the University of Athens, discusses phase III findings of the Andromeda study. Adding daratumumab to cyclophosphamide, bortezomib, and dexamethas...

Leukemia
Lymphoma

Elias Jabbour, MD, on Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Venetoclax and Navitoclax in Relapsed or Refractory Disease

Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings that showed venetoclax and navitoclax with chemotherapy is well tolerated, w...

Lymphoma
Immunotherapy

Elizabeth H. Phillips, MD, on DLBCL: Inotuzumab Ozogamicin Plus Chemotherapy in Front-Line Setting

Elizabeth H. Phillips, MD, of the University of Manchester and The Christie Hospital, discusses phase II findings showing inotuzumab ozogamicin plus rituximab, cyclophosphami...

Leukemia
Lymphoma

John C. Byrd, MD, on CLL/SLL: Acalabrutinib in Treatment-Naive Patients

John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, discusses the mature results of a phase II study showing durable remissions and long-term tolerabi...

Advertisement

Advertisement



Advertisement